Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True! - Journal of Diabetes Mellitus

JDM > Vol.6 No.2, May 2016

Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True! ()

HTML XML

Download as PDF (Size: 311KB) PP. 132-135

DOI: 10.4236/jdm.2016.62013 2,605 Downloads 3,439 Views Citations

Author(s)

Udaya M. Kabadi^1,2

Affiliation(s)

¹Broad Lawns Medical Center and Veterans Affairs Medical Center, Des Moines University, Des Moines, USA.
²University of Iowa, Iowa City, USA.

ABSTRACT

It was interesting to read the recent article regarding the efficacy of Empagliflozin in reducing all cause and cardiovascular mortality [1]. Superficially, the report appears to be very promising. However, the methodology, the results and the conclusions deserve and need further scrutiny and validation for several reasons.

KEYWORDS

Review Paper

Share and Cite:

Kabadi, U. (2016) Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!. Journal of Diabetes Mellitus, 6, 132-135. doi: 10.4236/jdm.2016.62013.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies